期刊论文详细信息
FEBS Letters
Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines
Ooishi, Hideo1  Tsuchida, Akira1  Itoh, Masaki1  Hirata, Manabu1  Hanada, Keiji1  Kajiyama, Goro1 
[1] First Department of Internal Medicine, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan
关键词: Cholecystokinin receptor;    Gelatinase;    Invasion;    Loxiglumide;    Matrix metalloproteinase-9;    CCK;    cholecystokinin;    DMEM;    Dulbecco's modified Eagle's medium;    ECM;    extracellular matrix;    FBS;    foetal bovine serum;    LXG;    loxiglumide;    MMP;    matrix metalloproteinase;   
DOI  :  10.1016/0014-5793(96)00245-1
学科分类:生物化学/生物物理
来源: John Wiley & Sons Ltd.
PDF
【 摘 要 】

Recently, cholecystokinin has been reported to be important in regulating the growth of pancreatic cancer. We investigated the effect of loxiglumide (LXG), a cholecytskinin receptor antagonist, on the invasiveness of two human pancreatic cancer cell lines. Cells were treated with LXG for 24 h, and examined in the invasion assay. The expression and activity of MMP-9 in supernatants from cancer cells were analyzed by Western blotting and zymogram. Interestingly, the invasiveness of cancer cells and expression of MMP-9 were decreased by LXG in a dose-dependent manner. LXG may be a useful therapeutic agent against pancreatic cancer.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201912020302554ZK.pdf 362KB PDF download
  文献评价指标  
  下载次数:5次 浏览次数:8次